Trending Now - Openai Introduces Gpt-rosalind for Life Sciences Research
WHO:
Axios - OpenAI introduced GPT-Rosalind, an AI model for life sciences research.
VentureBeat - The model is named after Rosalind Franklin, a chemist known for her contributions to the discovery of DNA’s structure.
VentureBeat - Initial customers include Moderna and Amgen.
VentureBeat - Sean Bruich, SVP of AI and Data at Amgen, commented on the collaboration.
VentureBeat - Stéphane Bancel, CEO of Moderna, highlighted the model's capabilities.
VentureBeat - Andy Hickl, CTO of the Allen Institute, noted the model's impact on data handling.
WHAT:
VentureBeat - GPT-Rosalind is designed to act as a specialized intelligence layer for life sciences research, shifting AI's role from a general-purpose assistant to a domain-specific "reasoning" partner.
VentureBeat - In granular testing via LABBench2, GPT-Rosalind achieved significant gains in CloningQA, a task requiring the end-to-end design of reagents for molecular cloning protocols.
VentureBeat - The model's submissions in a partnership with Dyno Therapeutics ranked above the 95th percentile of human experts on prediction tasks and reached the 84th percentile for sequence generation.
Techmeme - OpenAI launched GPT-Rosalind as a research preview specifically for customers in the life sciences sector, including drug discovery.
VentureBeat - GPT-Rosalind is the first in a new series of models optimized for scientific workflows, specifically designed to synthesize evidence, generate biological hypotheses, and plan experiments.
VentureBeat - In testing, GPT-Rosalind achieved the 84th percentile for sequence generation in a partnership with Dyno Therapeutics.
Axios - OpenAI launched GPT-Rosalind as a research preview for life sciences research.
VentureBeat - GPT-Rosalind is designed to synthesize evidence, generate biological hypotheses, and plan experiments.
VentureBeat - The model achieved leading performance on BixBench and outperformed GPT-5.4 on six out of eleven tasks in LABBench2.
VentureBeat - In a partnership with Dyno Therapeutics, GPT-Rosalind ranked above the 95th percentile of human experts in sequence-to-function prediction tasks.
VentureBeat - The model is launching with a new Life Sciences research plugin for Codex, available on GitHub.
WHERE:
VentureBeat - The model is available for qualified Enterprise customers in the United States.
WHEN:
VentureBeat - The model was launched in April 2026.
WHY:
VentureBeat - OpenAI's mission with GPT-Rosalind is to narrow the gap between a "promising scientific idea" and the actual "evidence, experiments, and decisions" required for medical progress.
VentureBeat - OpenAI aims to speed up the drug discovery process, which typically takes 10 to 15 years and requires billions of dollars in investment.
VentureBeat - The model is intended to address the fragmented workflows in scientific research.
HOW:
VentureBeat - The model is launching as a research preview specifically for qualified Enterprise customers in the United States, with restricted access built on principles of beneficial use, strong governance, and controlled access.
VentureBeat - Organizations requesting access to GPT-Rosalind must undergo a qualification and safety review to ensure they are conducting legitimate research with a clear public benefit.
VentureBeat - The model was developed with heightened enterprise-grade security controls and is part of a Trusted Access program, ensuring restricted access to approved users only.
VentureBeat - During the preview phase, the model will not consume existing credits or tokens, allowing researchers to experiment without immediate budgetary constraints.
VentureBeat - GPT-Rosalind was developed with heightened enterprise-grade security controls and is part of a Trusted Access program.
VentureBeat - The model connects to over 50 public multi-omics databases and literature sources, providing an orchestration layer for scientific workflows.
(UPDATED April 17, 2026 04:05 UTC)
OpenAI has unveiled GPT-Rosalind, a specialized intelligence layer aimed at enhancing life sciences research by transforming AI from a general assistant into a domain-specific reasoning partner. In testing, GPT-Rosalind demonstrated impressive performance, ranking above the 95th percentile of human experts in prediction tasks and achieving the 84th percentile for sequence generation, particularly in molecular cloning protocols. This model is being launched as a research preview for qualified Enterprise customers in the U.S., with access contingent on a rigorous qualification and safety review to ensure legitimate research with public benefits.
--
(UPDATED April 16, 2026 23:15 UTC)
OpenAI has launched GPT-Rosalind as a research preview tailored for the life sciences sector, including drug discovery, marking the first in a new series of models designed for scientific workflows. This model, developed with enhanced enterprise-grade security and part of a Trusted Access program, has already achieved the 84th percentile for sequence generation in collaboration with Dyno Therapeutics. During its preview phase, GPT-Rosalind will not use existing credits or tokens, allowing researchers to explore its capabilities without immediate budgetary concerns.
--
(UPDATED April 16, 2026 21:14 UTC)
OpenAI has launched GPT-Rosalind, an advanced AI model for life sciences research, named after the renowned chemist Rosalind Franklin, and it is now available for qualified Enterprise customers in the United States. This model is designed to synthesize evidence, generate biological hypotheses, and plan experiments, achieving top performance on various benchmarks and significantly enhancing the drug discovery process. Initial customers like Moderna and Amgen are already collaborating with GPT-Rosalind, which connects to over 50 public databases and literature sources to streamline scientific workflows.